Genentech Reports Second Interim Analysis Results from the P-III Study (SKYSCRAPER-01) of Tiragolumab + Tecentriq for PD-L1-High Metastatic Non-Small Cell Lung Cancer
Shots:
- The company provided updates on 2nd interim analysis of the P-III study evaluating tiragolumab (anti-TIGIT immunotherapy) + Tecentriq vs Tecentriq alone in a ratio (1:1) in 534 patients with PD-L1-high LA or metastatic NSCLC
- At the time of the second interim analysis, the 1EPs of OS were not mature with m-OS of 22.9 vs 16.7mos. The results also showed that the combination therapy was well tolerated with no new safety signals
- Tiragolumab, a novel immune checkpoint inhibitor with an intact Fc region that selectively binds to TIGIT & suppresses the immune response to cancer. Tecentriq is a mAb that binds to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with PD-1 and B7.1 receptors
Ref: Businesswire | Image: Genentech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
